<DOC>
	<DOCNO>NCT00592852</DOCNO>
	<brief_summary>This 12-week open-label pilot treatment study child adolescent ( age 6-17 ) meet DSM-IV criterion bipolar disorder ( BPD ) obsessive-compulsive disorder ( OCD ) adequately mood stabilized stable regimen base standard clinical care . Specific hypotheses follow : Hypothesis 1 : Children adolescent comorbid OCD BPD achieve adequate mood stabilization use naturalistic clinical practice approach , benefit FDA-approved selective seratonin reuptake inhibitor ( SSRI ) OCD symptom clinically meaningful way without exacerbation bipolar symptom .</brief_summary>
	<brief_title>Fluoxetine Obsessive-Compulsive Disorder Children Adolescents With Bipolar Disorder</brief_title>
	<detailed_description>As systemic data available regard efficacy safety selective serotonin reuptake inhibitor ( SSRI ) treatment OCD+BPD child , call preliminary open pilot treatment study explore issue logical first step could lead systematic randomize controlled trial future . SSRI 's first line commonly use anti-OCD agent . It remain unknown , standard SSRIs least activate youth BPD . Fluoxetine along fluvoxamine sertraline FDA approve treatment OCD child . Fluoxetine remain extensively study SSRI child . We test safety efficacy fluoxetine child adolescent BPD OCD . The propose study include 1 . ) use 12-week design document response rate 2 . ) careful assessment safety tolerability</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Male female participant 6 17 year age . Participants must DSMIV diagnosis OCD bipolar ( I II ) disorder , display current OCD symptom least moderate impairment ( CYBOCS ≥ 15 ) least 4 week prior participation maintain steady dose mood stabilize medication ( lithium , anticonvulsant atypical antipsychotic ) minimal mild mood symptom ( YMRS ≤ 15 ) . Period mood stabilization determine clinician judgment confirm KSADSE . Subject his/her legal representative must level understanding sufficient communicate intelligently investigator study coordinator , cooperate test examination require protocol . Subjects his/her legal representative must consider reliable . Each subject his/her authorized legal representative must understand nature study . The subject 's authorized legal representative subject must sign IRB approve informed consent assent document respectively . Subject must able participate mandatory blood draw . Subject must able swallow pill . Subjects comorbid ADHD , ODD , CD , anxiety disorder allow participate study provide meet exclusionary criterion . DSMIV substance dependence ( except nicotine caffeine ) within past 3 month . History antidepressant induce mania hypomania also treat appropriate dosage ( ) mood stabilizer . Pregnant nursing female . Investigator his/her immediate family , define investigator 's spouse , parent , child , grandparent , grandchild . Serious , unstable systemic illness . History severe allergy multiple adverse drug reaction . Nonfebrile seizures without clear resolve etiology . Clinically judge serious suicidal risk . Other concomitant medication primary central nervous system activity specify Concomitant Medication protocol . History allergic reaction SSRIs . Participants use MAOI within two week prior receive study medication . Current diagnosis schizophrenia . Uncorrected hypo hyperthyroidism . Active symptom anorexia bulimia nervosa Nonresponse OCD symptom fluoxetine define therapeutic dose fluoxetine least 10 week . Current treatment antidepressant medication .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>bipolar disorder</keyword>
	<keyword>obsessive compulsive disorder</keyword>
	<keyword>Prozac</keyword>
</DOC>